Try our beta test site

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

This study has been completed.
Information provided by:
Boehringer Ingelheim Identifier:
First received: September 7, 2005
Last updated: October 28, 2013
Last verified: October 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: No date given
  Primary Completion Date: March 2005 (Final data collection date for primary outcome measure)